114 unknown. 114 Phase 1, 58 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 114 | Unknown 114 |
| Phase 2 | 58 | Unknown 58 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma Anti-BCMA CAR-NK - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 10 | 2024-04-30 | 2024-03-06 |
| A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma CM313 injection - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Keymed Biosciences Co.Ltd | 120 | 2024-02-28 | 2023-11-13 |
| A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma KQ-2003 CAR T-cells - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | 29 | 2024-01-11 | 2024-01-25 |
| A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma QLS32015 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Unknown | Qilu Pharmaceutical Co., Ltd. | 100 | 2023-06-30 | 2023-06-27 |
| YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma YTS104 Cells injection - Relapsed or Refractory Multiple Myeloma | Phase 1 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2023-06-28 | 2025-08-15 |
| Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 20 | 2023-05-20 | 2023-05-15 |
| A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A) - Multiple Myeloma | Phase 1 | Unknown | Nanjing IASO Biotechnology Co., Ltd. | 12 | 2023-05-08 | 2023-01-26 |
| GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies GIC-102 - Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | GI Cell, Inc. | 50 | 2023-04-28 | 2024-07-09 |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Anti-GPRC5D CAR-T Cells Injection - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | XuYan | 18 | 2023-04-10 | 2023-04-20 |
| A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects TQB2934 injection - Multiple Myeloma | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 140 | 2023-03-17 | 2024-03-18 |
| AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma BCMA CAR-T cells injection - Multiple Myeloma | Phase 1 | Unknown | Zhejiang University | 50 | 2023-03-01 | 2023-02-23 |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Anti-GPRC5D CAR-T cells infusion - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 18 | 2023-02-07 | 2023-02-23 |
| Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma STI-6129 - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Sorrento Therapeutics, Inc. | 72 | 2023-02-01 | 2023-04-12 |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 181 | 2023-01-01 | 2023-01-05 |
| Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM melphalan hydrochloride for injection - Multiple Myeloma | Phase 1 | Unknown | Peking University People's Hospital | 24 | 2022-10-13 | 2023-04-14 |
| Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma STI-1492 - Multiple Myeloma | Phase 1 | Unknown | Sorrento Therapeutics, Inc. | 54 | 2022-10-01 | 2023-01-17 |
| CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma CXCR4 modified anti-BCMA CAR T cells - Multiple Myeloma | Phase 1 | Unknown | Sichuan University | 12 | 2022-09-21 | 2023-12-12 |
| Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma Anlotinib Hydrochloride Capsule - Multiple Myeloma | Phase 1 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2022-09-01 | 2022-09-22 |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma GC012F injection - Multiple Myeloma | Phase 1 | Unknown | Shanghai Changzheng Hospital | 9 | 2022-06-13 | 2022-07-26 |
Showing 20 of 114. Sign in to see all of them.
Recurrence (15) · Neoplasms, Plasma Cell (11) · Leukemia, Myeloid, Acute (8) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Myelodysplastic Syndromes (6) · Hodgkin Disease (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Breast Neoplasms (4) · Blood Protein Disorders (3) · Burkitt Lymphoma (3) · Hematologic Diseases (3) · Leukemia (3) · Lung Neoplasms (3)
Hemic and Lymphatic Diseases (114) · Cardiovascular Diseases (113) · Hemorrhagic Disorders (113) · Hemostatic Disorders (113) · Immune System Diseases (113) · Immunoproliferative Disorders (113) · Lymphoproliferative Disorders (113) · Neoplasms by Histologic Type (113) · Vascular Diseases (113) · Paraproteinemias (112) · Blood Protein Disorders (111) · Hematologic Diseases (111) · Neoplasms (111) · Neoplasms, Plasma Cell (103) · Pathological Conditions, Signs and Symptoms (20)
Dexamethasone (17) · Cyclophosphamide (10) · Bortezomib (8) · Lenalidomide (8) · fludarabine (6) · pomalidomide (5) · Bendamustine Hydrochloride (4) · Melphalan (4) · Thalidomide (3) · selinexor (3) · CT103A chimeric antigen receptor (2) · Immunotherapy, Adoptive (2) · Injections (2) · Lisaftoclax (2) · carfilzomib (2)
Oncotherapeutics (3) · Ascentage Pharma Group Inc. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Chinese PLA General Hospital (2) · Chong Kun Dang Pharmaceutical (2) · Chongqing Precision Biotech Co., Ltd (2) · Cylene Pharmaceuticals (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Keymed Biosciences Co.Ltd (2) · Nanjing IASO Biotechnology Co., Ltd. (2) · Peking Union Medical College Hospital (2) · Peter MacCallum Cancer Centre, Australia (2) · Second Affiliated Hospital of Xi'an Jiaotong University (2) · Shanghai Changzheng Hospital (2) · Shenzhen Second People's Hospital (2)
China (58) · United States (26) · Germany (4) · South Korea (4) · Australia (3) · Spain (3) · Canada (2) · United Kingdom (2) · Belgium (1) · France (1) · Greece (1) · Iran (1) · Ireland (1) · Israel (1) · Italy (1)
Gang An (2) · James R Berenson, MD (2) · Juan Du, MD (2) · Lugui Qiu (2) · Miles Prince, MD (2) · Wan-Hong Zhao, MD, PhD (2) · Yifan Zhai, MD, PhD (2) · Adrian Kilcoyne, MD (1) · Aibin Liang, MD, Ph.D (1) · Ajai Chari, MD (1) · Albrecht Reichle, Professor (1) · Arnon Nagler, MD (1) · Bingzong LI (1) · Bruce A Silver, M.D., FACP (1)
PMID 36100310, PMID 37192741, PMID 37658205, PMID 21911830, PMID 27442600, PMID 27843120, PMID 29133316, PMID 30572922, PMID 31201169, PMID 33112968, PMID 34213732, PMID 34471234, PMID 34876408, PMID 35546402, PMID 35651792, PMID 35794616, PMID 36536403, PMID 36764323, PMID 37270762, PMID 37414060, PMID 38467031, PMID 38659046, PMID 39031941, PMID 39313307, PMID 39602341, PMID 40232151, PMID 40737543, PMID 41160798
2019 (2)